Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03407976 · ClinicalTrials.gov registry record · Phase 1
Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
A Phase 1 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03407976 is a Phase 1 study that was terminated before completion, run by University of Utah. The registered enrollment target is 5 participants.
The verdict
NCT03407976, a Phase 1 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an open label nonrandomized Phase I/ IIA trial designed to assess the safety, tolerability, and efficacy of apatinib in combination with pembrolizumab. Phase I will assess the safety of combining increasing oral daily doses of apatinib with a fixed dose of IV pembrolizumab every three weeks and will determine the RP2D (Recommended Phase 2 Dose). Phase II will assess the efficacy of the RP2D of apatinib in combination with pembrolizumab and provide additional safety and tolerability data in three disease-specific cohorts
Interventions
- DRUG Pembrolizumab
- DRUG Apatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2020-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03407976
The ClinicalTrials.gov registry entry for NCT03407976 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03407976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03407976 about?
NCT03407976 is a clinical study titled "Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies". This is an open label nonrandomized Phase I/ IIA trial designed to assess the safety, tolerability, and efficacy of apatinib in combination with pembrolizumab. Phase I will assess the safety of combining increasing oral daily doses of apatinib with a fixed dose of IV pembrolizumab every three weeks ...
What is the current status of trial NCT03407976?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2018-06-19. Estimated completion is 2020-07-02.
What interventions are being tested in trial NCT03407976?
The interventions under investigation include: Pembrolizumab (DRUG), Apatinib (DRUG).
Who is sponsoring clinical trial NCT03407976?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.